Prognostic value of CD133+CD54+CD44+ circulating tumor cells in colorectal cancer with liver metastasis

Abstract

In the previous study, we had showed the expression of CD133⁺CD54⁺CD44⁺ cellular subpopulation of circulating tumor cells (CTCs) was significantly associated with liver metastasis of colorectal cancer (CRC). This study aimed to explore whether this subpopulation of CTCs have a prognostic value in CRC patients. Flow cytometry was used to detect the expression of cellular subpopulations of CTCs with CD133, CD54, and CD44 in 152 CRC patients, between December 2013 and October 2014. The impact of clinicopathological factors and the expression of cellular subpopulations of CTCs on overall survival were then analyzed. CRC patients with liver metastases who underwent resection of the primary tumor accompanied by surgical treatment for metastasis had a better survival than other patients (P < 0.001). The liver metastatic CRC patients with high expression of CD133⁺CD54⁺ (P < 0.001), CD133⁻CD54⁺ (P = 0.004), and CD133⁺CD44⁺CD54⁺ (P = 0.003) cellular subpopulations of CTCs had a worse survival than those patients with low expression. Multivariable survival analyses identified carcinoembryonic antigen levels (hazard ratio [HR] = 3.056; 95% confidence interval [CI] = 1.354–6.897; P = 0.007), treatment strategy (HR = 0.212; 95% CI = 0.056–0.808; P = 0.023), and CD133⁺CD44⁺CD54⁺ cellular subpopulation of CTCs (HR = 6.459; 95% CI = 1.461–28.558; P = 0.014) as independent prognostic factors for CRC patients with liver metastasis. CD133⁺CD44⁺CD54⁺ cellular subpopulation of CTCs has a prognostic value in CRC patients with liver metastasis, especially in the survival of CRC patients with liver metastasis who did not undergo surgical treatment for metastasis.

Surgical treatment of liver metastasis is important for the treatment of metastatic CRCs. CD133+CD44+CD54+ subpopulation of CTCs has the prognostic value in CRCs and affects the survival of CRCs without surgical treatment of metastases.

http://ift.tt/2zhEaBc